Scholar Rock Holding Corporation
SRRKHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeScholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating. With a market capitalization of $6.33B, it sits in mid-cap territory. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
Market Cap
$6.33B
Beta
0.68
P/E (TTM)
—
P/E (Fwd)
-22.30
EPS (TTM)
$-3.53
EPS (Fwd)
$-2.37
ROE
-138.9%
ROA
-54.3%
Cash
$479.9M
Total Debt
$205.7M
Free CF
-$171.9M
52W Change
29.8%
Annual Financials
Cash vs Debt
With $479.9M in cash and $205.7M in debt, SRRK maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$171.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -138.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $18.8M (2021) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Scholar Rock Holding Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SRRK.